Symbols / LQDA
LQDA Chart
About
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.92B |
| Enterprise Value | 2.96B | Income | -124.09M | Sales | 69.22M |
| Book/sh | 0.25 | Cash/sh | 1.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | 170 | IPO | — |
| P/E | — | Forward P/E | 12.46 | PEG | — |
| P/S | 42.19 | P/B | 132.17 | P/C | — |
| EV/EBITDA | -27.93 | EV/Sales | 42.80 | Quick Ratio | 1.88 |
| Current Ratio | 2.20 | Debt/Eq | 903.24 | LT Debt/Eq | — |
| EPS (ttm) | -1.46 | EPS next Y | 2.69 | EPS Growth | — |
| Revenue Growth | 11.22% | Earnings | 2026-02-26 | ROA | -25.35% |
| ROE | -187.21% | ROIC | — | Gross Margin | 89.11% |
| Oper. Margin | 3.25% | Profit Margin | -179.28% | Shs Outstand | 87.00M |
| Shs Float | 60.15M | Short Float | 18.22% | Short Ratio | 5.65 |
| Short Interest | — | 52W High | 46.67 | 52W Low | 11.26 |
| Beta | 0.47 | Avg Volume | 1.73M | Volume | 1.47M |
| Target Price | $43.00 | Recom | None | Prev Close | $32.74 |
| Price | $33.57 | Change | 2.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$43.00
Mean price target
2. Current target
$33.57
Latest analyst target
3. DCF / Fair value
$-18.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.57
Low
$16.00
High
$55.00
Mean
$43.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-16 | init | Scotiabank | — → Sector Outperform | $30 |
| 2024-10-03 | init | LifeSci Capital | — → Outperform | $30 |
| 2024-08-23 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-08-22 | reit | Needham | Buy → Buy | $19 |
| 2024-08-20 | main | BTIG | Buy → Buy | $25 |
| 2024-08-20 | main | B of A Securities | Buy → Buy | $23 |
| 2024-08-20 | main | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-08-19 | main | BTIG | Buy → Buy | $25 |
| 2024-08-19 | up | Raymond James | Outperform → Strong Buy | $27 |
| 2024-08-19 | reit | Needham | Buy → Buy | $25 |
| 2024-08-16 | init | Raymond James | — → Outperform | $27 |
| 2024-08-13 | reit | Needham | Buy → Buy | $25 |
| 2024-08-08 | main | Needham | Buy → Buy | $25 |
| 2024-07-18 | reit | Needham | Buy → Buy | $28 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-06-25 | init | Oppenheimer | — → Perform | — |
| 2024-06-03 | reit | Needham | Buy → Buy | $28 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-05-15 | reit | Needham | Buy → Buy | $28 |
| 2024-04-10 | reit | Needham | Buy → Buy | $28 |
- Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling - Yahoo Finance Mon, 16 Feb 2026 08
- Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? - Nasdaq hu, 15 Jan 2026 08
- Liquidia Corporation $LQDA is Patient Square Capital LP's 7th Largest Position - MarketBeat Mon, 23 Feb 2026 12
- $LQDA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- Liquidia Corporation (LQDA) Stock Analysis: Exploring 1,121.70% Revenue Growth and Strategic Opportunities - DirectorsTalk Interviews ue, 17 Feb 2026 14
- Liquidia: Won Many Patent Battles But The War Is Not Yet Won (undefined:LQDA) - Seeking Alpha Wed, 14 Jan 2026 08
- Biotech Developer Liquidia Corporation Set for Key Investor Presentation at Wells Fargo Healthcare Conference - Stock Titan Wed, 27 Aug 2025 07
- Liquidia (NASDAQ:LQDA) Shares Down 5% - Should You Sell? - MarketBeat Fri, 20 Feb 2026 19
- While Liquidia (NASDAQ:LQDA) shareholders have made 991% in 5 years, increasing losses might now be front of mind as stock sheds 9.3% this week - Yahoo Finance Fri, 13 Feb 2026 08
- LQDA April 2nd Options Begin Trading - Nasdaq hu, 12 Feb 2026 16
- $LQDA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Liquidia Corporation (LQDA) Stock Analysis: Exploring the 20% Upside Potential Amidst Groundbreaking Revenue Growth - DirectorsTalk Interviews ue, 20 Jan 2026 08
- GSA Capital Partners LLP Purchases New Shares in Liquidia Corporation $LQDA - MarketBeat Sat, 21 Feb 2026 11
- Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? - Yahoo Finance ue, 23 Sep 2025 07
- $LQDA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 09 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 688 | 28655.0 | — | Sale at price 41.65 per share. | ADAIR JASON | Officer | — | 2026-01-26 00:00:00 | D |
| 1 | 1580 | 65807.0 | — | Sale at price 41.65 per share. | BOYLE DANA | Officer | — | 2026-01-26 00:00:00 | D |
| 2 | 27683 | — | — | Stock Award(Grant) at price 0.00 per share. | ADAIR JASON | Officer | — | 2026-01-16 00:00:00 | D |
| 3 | 32955 | — | — | Stock Award(Grant) at price 0.00 per share. | MOOMAW SCOTT | Officer | — | 2026-01-16 00:00:00 | D |
| 4 | 32955 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHUNDLER RUSSELL | General Counsel | — | 2026-01-16 00:00:00 | D |
| 5 | 32955 | — | — | Stock Award(Grant) at price 0.00 per share. | SAGGAR RAJEEV | Officer | — | 2026-01-16 00:00:00 | D |
| 6 | 23728 | — | — | Stock Award(Grant) at price 0.00 per share. | KREPP SARAH | Officer | — | 2026-01-16 00:00:00 | D |
| 7 | 23728 | — | — | Stock Award(Grant) at price 0.00 per share. | BOYLE DANA | Officer | — | 2026-01-16 00:00:00 | D |
| 8 | 34274 | — | — | Stock Award(Grant) at price 0.00 per share. | KHINDRI SANJEEV | Officer | — | 2026-01-16 00:00:00 | D |
| 9 | 115344 | — | — | Stock Award(Grant) at price 0.00 per share. | JEFFS ROGER A | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -111.44M | -67.74M | -34.03M | -28.15M |
| TotalUnusualItems | -4.27M | -2.31M | -997.00K | -53.00K |
| TotalUnusualItemsExcludingGoodwill | -4.27M | -2.31M | -997.00K | -53.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.39M | -78.50M | -41.02M | -34.58M |
| ReconciledDepreciation | 2.20M | 2.18M | 3.65M | 5.61M |
| ReconciledCostOfRevenue | 5.88M | 2.89M | 2.86M | 3.02M |
| EBITDA | -115.71M | -70.05M | -35.03M | -28.20M |
| EBIT | -117.91M | -72.23M | -38.68M | -33.82M |
| NetInterestIncome | -4.83M | -2.81M | -1.25M | -729.00K |
| InterestExpense | 12.49M | 6.27M | 2.34M | 762.00K |
| InterestIncome | 7.65M | 3.47M | 1.09M | 33.00K |
| NormalizedIncome | -126.13M | -76.19M | -40.02M | -34.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.39M | -78.50M | -41.02M | -34.58M |
| TotalExpenses | 135.29M | 90.87M | 54.70M | 46.65M |
| TotalOperatingIncomeAsReported | -121.29M | -73.38M | -38.77M | -33.80M |
| DilutedAverageShares | 78.71M | 64.99M | 60.96M | 49.68M |
| BasicAverageShares | 78.71M | 64.99M | 60.96M | 49.68M |
| DilutedEPS | -1.66 | -1.21 | -0.67 | -0.70 |
| BasicEPS | -1.66 | -1.21 | -0.67 | -0.70 |
| DilutedNIAvailtoComStockholders | -130.39M | -78.50M | -41.02M | -34.58M |
| NetIncomeCommonStockholders | -130.39M | -78.50M | -41.02M | -34.58M |
| NetIncome | -130.39M | -78.50M | -41.02M | -34.58M |
| NetIncomeIncludingNoncontrollingInterests | -130.39M | -78.50M | -41.02M | -34.58M |
| NetIncomeContinuousOperations | -130.39M | -78.50M | -41.02M | -34.58M |
| PretaxIncome | -130.39M | -78.50M | -41.02M | -34.58M |
| OtherIncomeExpense | -4.27M | -2.31M | -997.00K | -53.00K |
| SpecialIncomeCharges | -4.27M | -2.31M | -997.00K | -53.00K |
| OtherSpecialCharges | 4.27M | 2.31M | 997.00K | 53.00K |
| NetNonOperatingInterestIncomeExpense | -4.83M | -2.81M | -1.25M | -729.00K |
| InterestExpenseNonOperating | 12.49M | 6.27M | 2.34M | 762.00K |
| InterestIncomeNonOperating | 7.65M | 3.47M | 1.09M | 33.00K |
| OperatingIncome | -121.29M | -73.38M | -38.77M | -33.80M |
| OperatingExpense | 129.41M | 87.98M | 51.85M | 43.63M |
| ResearchAndDevelopment | 47.84M | 43.24M | 19.43M | 20.52M |
| SellingGeneralAndAdministration | 81.57M | 44.74M | 32.41M | 23.11M |
| GeneralAndAdministrativeExpense | 81.57M | 44.74M | 32.41M | 23.11M |
| OtherGandA | 81.57M | 44.74M | 32.41M | 23.11M |
| GrossProfit | 8.12M | 14.60M | 13.08M | 9.83M |
| CostOfRevenue | 5.88M | 2.89M | 2.86M | 3.02M |
| TotalRevenue | 14.00M | 17.49M | 15.94M | 12.85M |
| OperatingRevenue | 14.00M | 17.49M | 15.94M | 12.85M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 84.68M | 68.63M | 64.52M | 52.29M |
| ShareIssued | 84.68M | 68.63M | 64.52M | 52.29M |
| TotalDebt | 122.39M | 49.54M | 24.46M | 16.08M |
| TangibleBookValue | 70.22M | 39.96M | 82.79M | 56.97M |
| InvestedCapital | 192.66M | 93.33M | 110.30M | 75.67M |
| WorkingCapital | 143.32M | 71.35M | 91.01M | 53.95M |
| NetTangibleAssets | 70.22M | 39.96M | 82.79M | 56.97M |
| CapitalLeaseObligations | 7.00M | 3.50M | 4.58M | 5.67M |
| CommonStockEquity | 77.28M | 47.29M | 90.42M | 65.27M |
| TotalCapitalization | 174.65M | 90.71M | 110.30M | 75.67M |
| TotalEquityGrossMinorityInterest | 77.28M | 47.29M | 90.42M | 65.27M |
| StockholdersEquity | 77.28M | 47.29M | 90.42M | 65.27M |
| RetainedEarnings | -559.49M | -429.10M | -350.60M | -309.58M |
| AdditionalPaidInCapital | 636.68M | 476.32M | 440.95M | 374.79M |
| CapitalStock | 85.00K | 69.00K | 64.00K | 52.00K |
| CommonStock | 85.00K | 69.00K | 64.00K | 52.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 153.04M | 71.04M | 38.78M | 28.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 111.26M | 52.49M | 29.98M | 21.14M |
| TradeandOtherPayablesNonCurrent | 7.30M | 6.71M | 6.59M | 6.14M |
| LongTermDebtAndCapitalLeaseObligation | 103.96M | 45.78M | 23.38M | 14.99M |
| LongTermCapitalLeaseObligation | 6.59M | 2.36M | 3.50M | 4.58M |
| LongTermDebt | 97.37M | 43.42M | 19.88M | 10.41M |
| CurrentLiabilities | 41.78M | 18.55M | 8.80M | 7.33M |
| CurrentDebtAndCapitalLeaseObligation | 18.43M | 3.75M | 1.08M | 1.09M |
| CurrentCapitalLeaseObligation | 417.00K | 1.14M | 1.08M | 1.09M |
| CurrentDebt | 18.02M | 2.62M | ||
| OtherCurrentBorrowings | 18.02M | 2.62M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 10.25M | 8.54M | 2.86M | 3.16M |
| PayablesAndAccruedExpenses | 13.10M | 6.25M | 4.86M | 3.08M |
| CurrentAccruedExpenses | 8.41M | 4.86M | 2.66M | 2.01M |
| Payables | 4.69M | 1.40M | 2.20M | 1.07M |
| OtherPayable | 2.62M | |||
| AccountsPayable | 4.69M | 1.40M | 2.20M | 1.07M |
| TotalAssets | 230.31M | 118.33M | 129.20M | 93.73M |
| TotalNonCurrentAssets | 45.21M | 28.43M | 29.39M | 32.45M |
| OtherNonCurrentAssets | 18.38M | 6.99M | 6.90M | 6.59M |
| NonCurrentPrepaidAssets | 6.28M | |||
| NonCurrentDeferredAssets | 7.29M | 7.92M | 8.60M | 10.14M |
| GoodwillAndOtherIntangibleAssets | 7.06M | 7.33M | 7.63M | 8.29M |
| OtherIntangibleAssets | 3.16M | 3.43M | 3.73M | 4.39M |
| Goodwill | 3.90M | 3.90M | 3.90M | 3.90M |
| NetPPE | 12.48M | 6.18M | 6.25M | 7.43M |
| AccumulatedDepreciation | -15.81M | -15.31M | -14.11M | -13.58M |
| GrossPPE | 28.29M | 21.50M | 20.37M | 21.01M |
| Leases | 12.96M | 11.41M | 11.41M | 11.46M |
| ConstructionInProgress | 3.00M | 804.00K | 155.00K | 0.00 |
| OtherProperties | 11.11M | 8.54M | 8.36M | 9.01M |
| MachineryFurnitureEquipment | 1.23M | 747.00K | 444.00K | 543.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 185.10M | 89.90M | 99.81M | 61.28M |
| OtherCurrentAssets | 5.67M | 2.16M | 1.51M | 792.00K |
| PrepaidAssets | 792.38K | |||
| Inventory | 241.00K | 0.00 | ||
| Receivables | 2.72M | 4.06M | 5.02M | 2.99M |
| AccountsReceivable | 2.72M | 4.06M | 5.02M | 2.99M |
| CashCashEquivalentsAndShortTermInvestments | 176.48M | 83.68M | 93.28M | 57.49M |
| CashAndCashEquivalents | 176.48M | 83.68M | 93.28M | 57.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -101.87M | -52.85M | -29.18M | -34.14M |
| RepaymentOfDebt | -4.96M | -24.02M | -10.81M | -10.83M |
| IssuanceOfDebt | 57.46M | 41.74M | 19.77M | 10.41M |
| IssuanceOfCapitalStock | 138.55M | 24.24M | 54.46M | 21.71M |
| CapitalExpenditure | -8.45M | -11.29M | -592.00K | -107.00K |
| InterestPaidSupplementalData | 0.00 | 360.00K | 1.63M | 423.00K |
| EndCashPosition | 176.48M | 83.68M | 93.28M | 57.49M |
| BeginningCashPosition | 83.68M | 93.28M | 57.49M | 65.32M |
| ChangesInCash | 92.80M | -9.60M | 35.79M | -7.82M |
| FinancingCashFlow | 194.66M | 43.25M | 64.96M | 26.32M |
| CashFlowFromContinuingFinancingActivities | 194.66M | 43.25M | 64.96M | 26.32M |
| NetOtherFinancingCharges | 593.00K | 113.00K | 451.00K | 4.99M |
| ProceedsFromStockOptionExercised | 3.02M | 1.18M | 1.10M | 41.00K |
| NetCommonStockIssuance | 138.55M | 24.24M | 54.46M | 21.71M |
| CommonStockIssuance | 138.55M | 24.24M | 54.46M | 21.71M |
| NetIssuancePaymentsOfDebt | 52.50M | 17.72M | 8.96M | -420.00K |
| NetLongTermDebtIssuance | 52.50M | 17.72M | 8.96M | -420.00K |
| LongTermDebtPayments | -4.96M | -24.02M | -10.81M | -10.83M |
| LongTermDebtIssuance | 57.46M | 41.74M | 19.77M | 10.41M |
| InvestingCashFlow | -8.44M | -11.29M | -587.00K | -107.00K |
| CashFlowFromContinuingInvestingActivities | -8.44M | -11.29M | -587.00K | -107.00K |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -3.50M | -10.00M | 0.00 | |
| PurchaseOfIntangibles | -3.50M | -10.00M | 0.00 | |
| NetPPEPurchaseAndSale | -4.94M | -1.29M | -587.00K | -107.00K |
| SaleOfPPE | 8.00K | 2.00K | 5.00K | 0.00 |
| PurchaseOfPPE | -4.95M | -1.29M | -592.00K | -107.00K |
| OperatingCashFlow | -93.42M | -41.56M | -28.59M | -34.03M |
| CashFlowFromContinuingOperatingActivities | -93.42M | -41.56M | -28.59M | -34.03M |
| ChangeInWorkingCapital | -4.79M | 5.87M | -2.16M | -12.38M |
| ChangeInOtherWorkingCapital | -102.73K | |||
| ChangeInOtherCurrentLiabilities | -970.00K | -900.00K | -775.00K | -2.43M |
| ChangeInOtherCurrentAssets | -10.63M | 20.00K | 4.00K | 80.00K |
| ChangeInPayablesAndAccruedExpense | 7.59M | 6.59M | 1.36M | -7.00M |
| ChangeInAccruedExpense | 5.26M | 7.75M | 545.00K | 563.00K |
| ChangeInPayable | 2.33M | -1.15M | 814.00K | -7.56M |
| ChangeInAccountPayable | 2.33M | -1.15M | 814.00K | -7.56M |
| ChangeInPrepaidAssets | -1.88M | -798.00K | -719.00K | -40.00K |
| ChangeInInventory | -241.00K | 0.00 | ||
| ChangeInReceivables | 1.34M | 956.00K | -2.03M | -2.99M |
| ChangesInAccountReceivables | 1.34M | 956.00K | -2.03M | -2.99M |
| OtherNonCashItems | 16.45M | 16.49M | 639.00K | 469.00K |
| StockBasedCompensation | 18.81M | 10.09M | 9.30M | 6.75M |
| DepreciationAmortizationDepletion | 2.20M | 2.18M | 3.65M | 5.61M |
| DepreciationAndAmortization | 2.20M | 2.18M | 3.65M | 5.61M |
| OperatingGainsLosses | 4.31M | 2.31M | 1.00M | 97.00K |
| GainLossOnSaleOfPPE | 46.00K | -2.00K | 4.00K | 44.00K |
| NetIncomeFromContinuingOperations | -130.39M | -78.50M | -41.02M | -34.58M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LQDA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|